Drug intelligence / Profile preview

rabeprazole + amoxicillin + clarithromycin + tetracycline

Development stage
Unknown
Lead developer
Buddhist Tzu Chi General Hospital
Modality
Small Molecules
Administration
Oral
01

Overview

5RA-5RCT is a specific 10-day sequential therapy regimen investigated by Buddhist Tzu Chi General Hospital for the eradication of Helicobacter pylori infection. The regimen is divided into two 5-day phases: the first phase consists of rabeprazole (20 mg b.i.d.) and amoxicillin (1000 mg b.i.d.), and the second phase consists of rabeprazole (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), and tetracycline (1000 mg b.i.d.). Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, thereby increasing the stability and efficacy of the antibiotics. Amoxicillin, clarithromycin, and tetracycline are antibiotics that target the bacterial cell wall and protein synthesis machinery to eliminate the H. pylori infection. This sequential approach aims to improve eradication rates compared to standard triple therapy, particularly in regions with high antibiotic resistance.

Other names
5RA-5RCTSequential therapy (rabeprazole, amoxicillin, clarithromycin, tetracycline)
02

Targets

H. pylori 50S subunit (Helicobacter pylori 50S ribosomal subunit)PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)Bacterial Ribosome

Beyond the preview

Go deeper on rabeprazole + amoxicillin + clarithromycin + tetracycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabeprazole + amoxicillin + clarithromycin + tetracycline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call